SMO protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “SMO protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in SMO protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
SMO protein inhibitors: Overview
SMO is a G-protein-coupled receptor (GPCR) of the Frizzled-class (class-F). It transduces the Hedgehog signal from the tumour suppressor Patched-1 (PTCH1) to the glioma-associated-oncogene (GLI) transcription factors, which activates the Hedgehog signalling pathway. Mutations in SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma. Overexpression of either Wnt-1 or the GLI proteins results in cancer. Inhibition of the Smoothened (SMO) protein prevents the induction of GLI transcriptional activity upon exposure of cancer cells to Shh ligands. Loss of induction of GLIs upon activation of Shh signaling inhibits the ability of Shh signaling to promote tumor progression. Therapies that inhibit Smo have many applications in cancer treatment, therefore several active clinical trials are going on to check efficacy.
Report Highlights
This segment of the SMO protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
SMO protein inhibitors Emerging Drugs
Further product details are provided in the report……..
SMO protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different SMO protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
SMO protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses SMO protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging SMO protein inhibitors drugs.
SMO protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “SMO protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in SMO protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
SMO protein inhibitors: Overview
SMO is a G-protein-coupled receptor (GPCR) of the Frizzled-class (class-F). It transduces the Hedgehog signal from the tumour suppressor Patched-1 (PTCH1) to the glioma-associated-oncogene (GLI) transcription factors, which activates the Hedgehog signalling pathway. Mutations in SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma. Overexpression of either Wnt-1 or the GLI proteins results in cancer. Inhibition of the Smoothened (SMO) protein prevents the induction of GLI transcriptional activity upon exposure of cancer cells to Shh ligands. Loss of induction of GLIs upon activation of Shh signaling inhibits the ability of Shh signaling to promote tumor progression. Therapies that inhibit Smo have many applications in cancer treatment, therefore several active clinical trials are going on to check efficacy.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence SMO protein inhibitors R&D. The therapies under development are focused on novel approaches for SMO protein inhibitors.
This segment of the SMO protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
SMO protein inhibitors Emerging Drugs
- GT1708F: Suzhou Kintor Pharmaceuticals
- ENV-101: Endeavor BioMedicines
Further product details are provided in the report……..
SMO protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different SMO protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on SMO protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
SMO protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses SMO protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging SMO protein inhibitors drugs.
SMO protein inhibitors Report Insights
- SMO protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing SMO protein inhibitors drugs?
- How many SMO protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for SMO protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the SMO protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for SMO protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pfizer
- Endeavor BioMedicines
- PellePharm
- Sun Pharmaceutical Industries
- Roche
- Guangdong Zhongsheng Pharmaceutical
- Suzhou Kintor Pharmaceuticals
- Glasdegib
- ENV-101
- Patidegib
- Sonidegib
- Vismodegib
- ZSP1602
- GT1708F
Introduction
Executive Summary
SMO protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
SMO protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
SMO protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
SMO protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Patidegib: PellePharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
ENV-101: Endeavor BioMedicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
SMO protein inhibitors Key Companies
SMO protein inhibitors Key Products
SMO protein inhibitors- Unmet Needs
SMO protein inhibitors- Market Drivers and Barriers
SMO protein inhibitors- Future Perspectives and Conclusion
SMO protein inhibitors Analyst Views
SMO protein inhibitors Key Companies
Appendix
Executive Summary
SMO protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
SMO protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
SMO protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
SMO protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Patidegib: PellePharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
ENV-101: Endeavor BioMedicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
SMO protein inhibitors Key Companies
SMO protein inhibitors Key Products
SMO protein inhibitors- Unmet Needs
SMO protein inhibitors- Market Drivers and Barriers
SMO protein inhibitors- Future Perspectives and Conclusion
SMO protein inhibitors Analyst Views
SMO protein inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for SMO protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for SMO protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for SMO protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for SMO protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
